Heidi Fettke

Dr. Heidi Fettke


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in European Urology
Verified
Journal Article
Closed access
HFHeidi Fettke
Heidi Fettke
EKEdmond M. Kwan
Edmond M. Kwan
MDMaria M. Docanto
Maria M. Docanto
PBPatricia Bukczynska
Patricia Bukczynska
NNNicole Ng
Nicole Ng
AAArun A. Azad
Arun A. Azad

26 October 2018 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
HFHeidi Fettke
Heidi Fettke
EKEdmond M. Kwan
Edmond M. Kwan
AAArun A. Azad
Arun A. Azad

5 August 2023 in EBioMedicine
Verified
Journal Article
Open access
HFHeidi Fettke
Heidi Fettke
CDChao Dai
Chao Dai
EKEdmond M. Kwan
Edmond M. Kwan
TZTiantian Zheng
Tiantian Zheng
PDPan Du
Pan Du
AAArun A. Azad
Arun A. Azad
Genomic alterations in DNA damage response (DDR) genes are common in metastatic castration-resistant prostate cancer (mCRPC). Understanding how these genomic events impact prognosis and/or treatment response is vital for optimising clinical outcomes. Targeted sequencing was performed on 407 plasma samples from 375 men with mCRPC. Using the CLIA-certified PredicineCARE™ cell-free DNA (cfDNA) assay, pathogenic alterations in 152 key genes (including 27 DDR-related genes) were assessed, as was the presence and mechanisms of biallelic loss in BRCA2. At least one DDR alteration was present in 34.5% (129/375) of patients (including monoallelic alterations). The most frequently altered DDR genes were BRCA2 (19%), ATM (13%), FANCA (5%), CHEK2 (5%) and BRCA1 (3%). Patients with BRCA alterations, especially BRCA2, had significantly worse progression-free survival (PFS) (Hazard ratio (HR) 3.3 [95% CI 1.9–6.0]; Cox regression p < 0.001), overall survival (HR 2.2 [95% CI 1.1–4.5]; Cox regression p = 0.02) and PSA response rates to androgen receptor (AR) pathway inhibitors (32% vs 60%, chi-square p = 0.02). BRCA-deficient tumours were also enriched for alterations within multiple genes including in the AR and PI3K pathways. Zygosity of BRCA2 alterations had no discernible impact on clinical outcomes, with similarly poor PFS for monoallelic vs biallelic loss (median 3.9 months vs 3.4 months vs copy neutral 9.8 months). These data emphasise that the BRCA genes, in particular BRCA2, are key prognostic biomarkers in mCRPC. The clinical utility of BRCA2 as a marker of poor outcomes may, at least in cfDNA assays, be independent of the zygosity state detected. Enrichment of actionable genomic alterations in cfDNA from BRCA-deficient mCRPC may support rational co-targeting strategies in future clinical trials. Several funding sources have supported this study. A full list is provided in the Acknowledgments. No funding was received from Predicine, Inc. during the conduct of the study.

1 June 2018 in European Urology
Verified
Journal Article
Closed access
STSarah Q. To
Sarah Q. To
EKEdmond M. Kwan
Edmond M. Kwan
HFHeidi Fettke
Heidi Fettke
AMAndrew Mant
Andrew Mant
MDMaria M. Docanto
Maria M. Docanto
AAArun A. Azad
Arun A. Azad

1 November 2021 in JCO Precision Oncology
Verified
Journal Article
Closed access
EKEdmond Kwan
Edmond Kwan
CDChao Dai
Chao Dai
HFHeidi Fettke
Heidi Fettke
CHChristine Hauser
Christine Hauser
MDMaria M. Docanto
Maria M. Docanto
AAArun A. Azad
Arun A. Azad
PURPOSE: Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs in plasma cell–free DNA (cfDNA) has proven to be challenging. With emerging data supporting Akt inhibition in PTEN-deficient mCRPC, we profiled PTEN-PI3K-AKT pathway aberrations in patients with mCRPC using a novel cfDNA assay optimized for CNV detection.METHODS: A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from two independent cohorts (Australian, n = 78; United States, n = 153). PTEN-PI3K-AKT pathway genomic aberrations were correlated with clinical outcomes, including progression-free survival and overall survival (OS).RESULTS: PTEN loss and PIK3CA gain were detected in 37% (85 of 231) and 17% (39 of 231) of patients, respectively. Poorer outcomes were observed in patients with PTEN-PI3K-AKT pathway aberrations, including those with dual PTEN loss and PIK3CA gain (hazard ratio 2.3, 95% CI 1.2 to 4.4). Cumulative CNV burden in the PTEN-PI3K-AKT and androgen receptor (AR) pathways was associated with significantly worse clinical outcomes (0 v 1 v ≥ 2 CNVs in Australian cohort: median OS 33.5 v 17.2 v 9.7 months, P < .001; 0 v 1 v ≥ 2 CNVs in US cohort: median OS 35.5 v 14.3 v 9.2 months, P < .001). Notably, 21% (31 of 146) of PTEN-neutral patients harbored alternative PTEN-PI3K-AKT pathway aberrations.CONCLUSION: PTEN-PI3K-AKT pathway CNVs were readily detected using our cfDNA assay, with the prevalence of PTEN loss comparable with tissue-based studies. Additional PTEN-PI3K-AKT pathway aberrations were found in one fifth of PTEN-neutral cases. Concurrent CNVs in the PTEN-PI3K-AKT and AR pathways portended poor survival, and identifying this high-risk patient subset for dual AR/Akt inhibition may optimize precision treatment with Akt inhibitors in mCRPC.

1 November 2021 in European Urology Focus
Verified
Journal Article
Closed access
HFHeidi Fettke
Heidi Fettke
EKEdmond Kwan
Edmond Kwan
PBPatricia Bukczynska
Patricia Bukczynska
NNNicole Ng
Nicole Ng
TNTu Nguyen-Dumont
Tu Nguyen-Dumont
AAArun A. Azad
Arun A. Azad